Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Ductal Carcinoma in Situ
Interventions: DRUG: SOM 230 / Pasireotide
Sponsor: NYU Langone Health